The trial randomized 18,201 patients with nonvalvular Afib to take apixaban or warfarin. The ARISTOTLE trial was a multicenter, double-blind, comparative trial. In patients with Afib, apixaban has been shown to be better than warfarin at reducing the risk of stroke. “Apixaban has been shown to cause less major bleeding in patients compared to warfarin,” explained Fanikos, citing the ARISTOTLE trial. Fibrin creates a weblike structure that catches blood platelets and other molecules, which then bind together to form a blood clot.Īpixaban is just as effective, if not more so, than warfarin. Interrupting the clotting cascade ultimately stops a structure called fibrin from forming. They bind to factor Xa and stop it from continuing the clotting process,” explained John Fanikos, RPh, MBA, Director of Pharmacy Services for Brigham and Women’s Hospital. “The factor Xa inhibitors interrupt the process that allows blood to clot, known as the clotting cascade. The FDA first approved the drug in December 2012 and then signed off on a generic formulation in December 2019.Īpixaban is a direct factor Xa inhibitor. Patients are generally prescribed 5 mg or 2.5 mg doses, which can be taken with or without food. Apixaban comes in a tablet form and should be taken twice a day. DOACs include apixaban, betrixaban, dabigatran, edoxaban, and rivaroxaban.Īpixaban (Eliquis ®), is an anticoagulant that reduces a patient’s risk of developing a blood clot, which can cause deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke from atrial fibrillation (Afib). DOACs are as effective and safer than warfarin, especially with regard to serious bleeding episodes. For the past several decades, warfarin has been the go-to anticoagulant (sometimes called a blood thinner), but newer treatments have emerged in the form of direct oral anticoagulants (DOACs).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |